As a result of a number of recently reported equine fatalities associated with the use of Medroxyprogesterone (MPA), US Equestrian will reconvene its MPA Panel to further analyze the use of this substance in horses competing at USEF-licensed competitions.
This latest information on equine fatalities associated with the use of MPA underscores the need for the MPA Panel to meet and review the critical information about this substance in order to provide our members with the information they need to protect their equine partners.
The MPA Panel was first convened in the winter to 2017 due to discussion in the veterinary community and the emergence of research regarding the efficacy of MPA in competition horses. Specifically, the question focused on how MPA affects the competition horse, since research indicated that MPA does not interrupt estrus in mares. This was especially important due to its increased use in geldings and stallions, and also to the reports of increased dosages being administered.
Following discussions at public hearings and town halls, as well as feedback from our members, the MPA Panel recommended that we continue to monitor the use of MPA, including implementation of MPA-specific medication reports in order to capture more information on dosage, administration schedules, and the continued presence of the substance in a horse’s system after the last known administration. However, the recent reports of equine fatalities have raised greater concern regarding the safety of this substance in horses.
US Equestrian remains steadfast in our efforts to protect human and equine athletes. As such, we will update our membership on any changes to the permitted use of MPA. In the interim, USEF strongly discourages the use of MPA by its members and also recommends that you consult with your veterinarian.
If you were involved in equestrian sports at all last year, you probably noticed how COVID incentivized the industry to make a few changes in day-to-day business operations. The United States Eventing Association (USEA) caught up with the STRIDER leadership team to learn more about recent industry trends after their trip earlier this month to EQUITANA USA at the Kentucky Horse Park.
US Equestrian is pleased to announce two additional competitions approved by the USEF Board of Directors to host CCI4*-S, CCI3*-L, and Advanced level events during the 2023-2027 competition cycle under the new Eventing Calendar Process. The Florida Horse Park has been allocated the CCI4*-S, CCI3*-L, and Advanced levels on Week 16 and the Advanced level on Week 40.
If you take one look at Jim Moyer’s Facebook page, you will see it is filled with sweet sentiments from the lives he has touched through his work in the equine industry. Moyer’s involvement with horses began when he met his future wife Jean 50 years ago. As Jean went on to become a prominent instructor in eventing, Moyer found that their friend circle was full of horse people, so it was only natural that he should find his place in the community.
Horses and riders in 12 divisions, from Starter to CCI4*-S, tackled the show jumping phase of competition Sunday at The Event at TerraNova, over a track designed by Nick Granat in the world-class setting of the main arena. Prize money was awarded in all divisions.